Claims for Patent: 9,918,970

Summary for Patent: 9,918,970

Title:	Pharmaceutical composition comprising solifenacin
Abstract:	Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.
Inventor(s):	Yoshioka; Tatsunobu (Tokyo, JP), Murai; Makoto (Tokyo, JP), Tasaki; Hiroaki (Tokyo, JP)
Assignee:	Astellas Pharma Inc. (Tokyo, JP)
Application Number:	13/110,295
Patent Claims:	1. A pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and polacrilin potassium, and Carbomer Homopolymer Type B, wherein the pharmaceutical composition is a rapid release suspension in which the complex is uniformly dispersed in water, and a water soluble liquid solvent comprising the Carbomer Homopolymer Type B, and the pH of the suspension is 5.4 to 7.0; and wherein the blending amount ratio by weight of solifenacin to polacrilin potassium is from 1:2 to 1:4, and the viscosity of the suspension is from 116 cPs to 987 cPs, when the viscosity is determined at 25.degree. C. using a rotational viscometer at 100 rpm, and, wherein the blending amount ratio by weight of the Carbomer Homopolymer Type B to solifenacin or a pharmaceutically acceptable salt thereof and polacrilin potassium is 0.25 to 1. 2. The pharmaceutical composition according to claim 1, wherein the pH is between about 6 and about 7. 3. The pharmaceutical composition according to claim 1, wherein the suspension is a preparation for oral administration. 4. The pharmaceutical composition according to claim 1, wherein the concentration of the Carbomer Homopolymer Type B in water, and the water soluble liquid solvent is from 1.6 mg/ml or more to 3 mg/ml or less. 5. The pharmaceutical composition according to claim 1, wherein 85% or more of solifenacin is released in 15 minutes in a dissolution test performed by the paddle method at a paddle speed of 50 rpm wherein the fluid for the dissolution test is 0.1 N hydrochloric acid. 6. The pharmaceutical composition according to claim 1, wherein the water soluble liquid solvent is one or more members selected from the group consisting of propylene glycol, or glycerin.